About Index Trending news
Analyze
Pricing
Cytori Therapeutics

Cytori Therapeutics

Work at Cytori Therapeutics? Add yourself to this profile

Cytori Therapeutics

Developing cell therapies for significant medical conditions including hand scleroderma, knee osteoarthritis, thermal burns and stress urinary incontinence.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
Post-IPO equity
$17,100,000
Post-IPO equity
$13,500,000
Employees

Team size

50+
Locations
HQ
Acquisition
Xconomy

Cytori Buys San Antonio-based Azaya’s Drug Delivery Tech for Stock

Health
$17,100,000 Post-IPO equity
businesswire , MassDevice

Cytori Closes Rights Offering for Gross Proceeds of $17.1 Million | Business Wire